ERBB3 is altered in 3.19% of malignant solid tumor patients [3].

ERBB3 is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 6 are open and 1 is closed. Of the trials that contain ERBB3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

ERBB3 is altered in 1.93% of non-small cell lung carcinoma patients [3].

ERBB3 is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain ERBB3 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

ERBB3 is altered in 2.71% of breast carcinoma patients [3].

ERBB3 is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ERBB3 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 4.97% of colorectal carcinoma patients [3].

ERBB3 is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain ERBB3 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 10.68% of bladder carcinoma patients [3].

ERBB3 is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 3.62% of melanoma patients [3].

ERBB3 is an inclusion criterion in 3 clinical trials for melanoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and melanoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 1.92% of ovarian carcinoma patients [3].

ERBB3 is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 1.76% of pancreatic carcinoma patients [3].

ERBB3 is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 10.77% of urothelial carcinoma patients [3].

ERBB3 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

ERBB3 is altered in 7.67% of gastric carcinoma patients [3].

ERBB3 is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is altered in 5.37% of cervical carcinoma patients [3].

ERBB3 is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 4.42% of adenocarcinoma of the gastroesophageal junction patients [3].

ERBB3 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERBB3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 3.31% of head and neck squamous cell carcinoma patients [3].

ERBB3 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 2.81% of head and neck carcinoma patients [3].

ERBB3 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is altered in 1.33% of hepatocellular carcinoma patients [3].

ERBB3 is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is altered in 11.28% of gallbladder carcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is altered in 8.48% of endometrial carcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is altered in 7.73% of gastric adenocarcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is altered in 7.3% of malignant uterine neoplasm patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is altered in 5.79% of esophageal squamous cell carcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is altered in 5.34% of biliary tract neoplasm patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is altered in 3.72% of bile duct carcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is altered in 2.52% of anaplastic astrocytoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is altered in 2.47% of glioblastoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is altered in 1.92% of lung carcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is altered in 1.85% of soft tissue sarcoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is altered in 2.01% of sarcoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is altered in 1.77% of pancreatic adenocarcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is altered in 1.17% of prostate carcinoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is altered in 1.06% of lymphoma patients [3].

ERBB3 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].